Zynex (ZYXI) Projected to Post Earnings on Tuesday

Zynex (NASDAQ:ZYXI) is anticipated to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Zynex to post earnings of $0.09 per share and revenue of $53.65 million for the quarter.

Zynex Price Performance

NASDAQ ZYXI opened at $7.23 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex has a 12-month low of $7.01 and a 12-month high of $13.19. The company has a market capitalization of $230.25 million, a PE ratio of 48.20 and a beta of 0.54. The firm’s 50 day moving average is $7.79 and its 200-day moving average is $8.03.

Insider Buying and Selling at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the sale, the chief financial officer now owns 19,738 shares of the company’s stock, valued at approximately $151,587.84. The trade was a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 30,000 shares of company stock worth $227,100 over the last ninety days. Insiders own 52.13% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Zynex in a report on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.